Citeline, a Norstella company

A new survey from Grand Avenue Software found 54% of life sciences firms were no more than “moderately” prepared for the FDA’s new Quality Management System Regulation at its February roll-out. Staffing and financial limitations, regulatory complexity, and lack of collaboration were common concerns.

Going public via a reverse merger with Cyclerion and raising $380m, Korsana hopes to position preclinical KRSA-028 as a better amyloid-targeting shuttled antibody for Alzheimer’s.

The hotly anticipated approval of orforglipron for obesity came through in record time, with the company planning to start shipping it on April 6.

Centessa’s lead drug candidates are being tested in narcolepsy and hypersomnia, but the orexin pathway has potential in an array of CNS disorders.

Insilico Medicine and Eli Lilly strike another deal, this time giving the US giant global rights to a set of undisclosed preclinical assets at the Chinese firm.

From once-daily and weekly oral small molecules to monthly injectable GLP-1R agonists and non-incretin candidates, multiple Chinese firms are rapidly progressing their programs in weight reduction.

Through partnerships overseas, China’s pharma companies are looking to build in-house capabilities in the long run, while domestic biotechs are adjusting their own strategies to drive growth.

Biokin reports at ELCC strong survival results from a Phase II trial of iza-bren combined with an anti-PD-1 antibody for the first-line treatment of extensive-stage small cell lung cancer, paving the way for more studies of combo regimens comprising the ADC and immuno-oncology agents.